

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/237065542>

# Molecular docking and quantitative structure activity relationship (QSAR) analyses of indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors. Med Chem Res (in...

ARTICLE in MEDICINAL CHEMISTRY RESEARCH · JANUARY 2013

Impact Factor: 1.4 · DOI: 10.1007/s00044-013-0647-8.

CITATIONS

7

READS

47

7 AUTHORS, INCLUDING:



Vijay H. Masand

Vidya Bharati College, Amravati, Maharasht...

69 PUBLICATIONS 298 CITATIONS

SEE PROFILE



Taibi Ben Hadda

Université Mohammed Premier

338 PUBLICATIONS 1,437 CITATIONS

SEE PROFILE



Rahul Jawarkar

35 PUBLICATIONS 161 CITATIONS

SEE PROFILE



Harsh Chauhan

Creighton University

22 PUBLICATIONS 85 CITATIONS

SEE PROFILE

*Molecular docking and quantitative structure–activity relationship (QSAR) analyses of indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors*

**Vijay H. Masand, Devidas T. Mahajan, Taibi Ben Hadda, Rahul D. Jawarkar, Hemant Chavan, B. P. Bandgar & Harsh Chauhan**

**Medicinal Chemistry Research**

ISSN 1054-2523

Med Chem Res

DOI 10.1007/s00044-013-0647-8



**Your article is protected by copyright and all rights are held exclusively by Springer Science +Business Media New York. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at [link.springer.com](http://link.springer.com)".**

# Molecular docking and quantitative structure–activity relationship (QSAR) analyses of indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors

Vijay H. Masand · Devidas T. Mahajan · Taibi Ben Hadda ·  
Rahul D. Jawarkar · Hemant Chavan · B. P. Bandgar ·  
Harsh Chauhan

Received: 16 January 2013 / Accepted: 22 May 2013  
© Springer Science+Business Media New York 2013

**Abstract** Indolylarylsulfones (IASs) have received considerable interest during the last decades due to high potency against HIV-1 as non-nucleoside reverse transcriptase inhibitors. In present work, quantitative structure–activity relationship (QSAR) and molecular docking analyses were performed to model the anti-HIV-1 activity of 36 IASs. 2D and 3D-descriptors, genetic algorithm, internal and external validations were used to develop statistically robust four-parametric QSAR models. The best QSAR model is with  $R_{tr}^2 = 0.8608$ . The QSAR analysis reveals that the activity of IASs depends on the presence of electronegative and heavy atoms at the internal atmosphere of the compounds. The docking analysis reveals that lipophilic and H-bonding interactions are the prominent interactions among IASs and the receptor. The QSAR analysis proved to be a useful tool in the prediction of anti-HIV-1 activity of congeneric compounds and some important

insights were also found that will be useful to guide for the synthesis of new IASs with improved activity.

**Keywords** Molecular docking · QSAR · Indolylarylsulfones · HIV-1

## Abbreviations

|        |   |
|--------|---|
| QSAR   | Quantitative structure–activity relationship    |
| NNRTIs | Non-nucleoside reverse transcriptase inhibitors |
| IASs   | Indolylarylsulfones                             |
| WHO    | World Health Organization                       |
| AIDS   | Acquired Immunodeficiency Syndrome              |
| HAART  | Highly active antiretroviral therapy            |
| RT     | Reverse transcriptase                           |
| GA     | Genetic algorithm                               |

V. H. Masand (✉) · D. T. Mahajan  
Department of Chemistry, Vidya Bharati College, Camp,  
Amravati, Maharashtra, India  
e-mail: vijaymasand@gmail.com; vijaymasand@rediffmail.com

T. B. Hadda  
Laboratoire Chimie des Matériaux, Université Mohammed  
Premier, 60000 Oujda, Morocco

R. D. Jawarkar  
Department of Pharmaceutical Chemistry, P. Wadhvani  
College of Pharmacy, Dhamangaon Rly. Road, Yavatmal,  
Maharashtra, India

H. Chavan  
Department of Chemistry, Solapur University, Solapur,  
Maharashtra, India

B. P. Bandgar · H. Chauhan  
Creighton University, Greater Boston Area, Omaha, USA

## Introduction


Human Immunodeficiency Virus (HIV), the etiological agent of Acquired Immunodeficiency Syndrome (AIDS), is a major health problem in many countries. World Health Organization (WHO) and many other agencies are actively engaged in prevention and treatment of this dreadful disease (WHO Report, 2011). New drugs and therapies are being developed to diagnose, prevent, control, and cure this lethal disease. The life cycle of HIV has been remarkably analyzed, which has led to identification of many of its steps as attractive targets for drug designing. The highly active antiretroviral therapy (HAART), in which three (recommended) or four different antiretroviral drugs are used, for HIV inhibition is chiefly based on the inhibition of three key viral enzymes: HIV-1 reverse transcriptase

(RT), HIV-1 protease, and HIV-1 integrase. Among these proteins that are crucial in life cycle of HIV, the inhibition of RT, which does not exist in Human and play an important role in the viral replication, is considered as one of the most attractive target in the anti-HIV chemotherapy. The emergence of resistance against many drugs used in HAART is a cause of serious concern. Thereby, development of new drugs or modification of existing drugs is essential to restrain HIV-1. These important goals can be achieved using modern methods of drug designing viz. QSAR, Molecular docking, pharmacophore modeling, etc. (Mahajan *et al.*, 2012, 2013; Masand *et al.*, 2010, 2012, 2013).

Among these techniques, QSAR and molecular docking are thriving techniques that have gained considerable attention because of good success. The central theme and application of QSAR is to establish the correlation between structure and biological response, whereas molecular docking is performed to determine the structural features that are important for interaction with a receptor (Doweyko, 2008; Mahajan *et al.*, 2012, 2013; Masand *et al.*, 2010, 2012, 2013). In present study, we have performed QSAR and docking analysis to determine the pharmacophoric features and conformation that steers the anti-HIV-1 activity of IASs.

## Dataset and descriptor calculation

The dataset selected (La Regina *et al.*, 2011) for present study includes 36 IASs possessing a variety of substituents at various positions (Fig. 1; Table 1). The HIV-1 RT inhibitory activity reported as  $IC_{50}$  (nM) was converted to  $-\log_{10}IC_{50} = pIC_{50}$  (M). The structures were drawn and optimized using default settings in ACD ChemSketch 12. e-Dragon was used to calculate variety of 2D and 3D descriptors.



**Fig. 1** IASs used in present study

## QSAR model development

Genetic algorithm (GA) module available in QSARINS (Chirico and Gramatica, 2011, 2012; Gramatica, 2013) was used to select optimum number and set of descriptors. In present analysis, two QSAR equations were developed for complete dataset ( $N = 36$ ) and by dividing it into training set ( $N_{tr} = 29$ ) and test set ( $N_{ex} = 7$ ) randomly, for better external validation (Golbraikh and Tropsha, 2002; Gramatica *et al.*, 2007; Gramatica and Papa, 2007; Mahajan *et al.*, 2012, 2013; Martin *et al.*, 2012; Masand *et al.*, 2010, 2012, 2013; Sushko *et al.*, 2010; Tropsha 2010).

### QSAR models

The GA-MLR QSAR models along with their statistical characteristics and interpretation are as following:

$$pIC_{50} = 10.7963 - 0.0549RDF105m - 17.9976G2e + 0.1892H - 048 + 0.1604F07[C - S] \quad (\text{Model 1})$$

$$N_{tr} = 36, Q_{loo}^2 = 0.7779, R_{tr}^2 = 0.8608, R_{adj}^2 = 0.8428, K_{xx} = 0.3179, \Delta K = 0.1425, RMSE_{tr} = 0.1595, RMSE_{cv} = 0.2015, Sy = 0.1719, F = 47.9201, CCC_{tr} = 0.9252, CCC_{cv} = 0.8795, MAE_{tr} = 0.1227, MAE_{cv} = 0.1488, RSS_{tr} = 0.9160, PRESS_{cv} = 1.4612, R_{LMO}^2 = 0.8695, Q_{LMO}^2 = 0.7999.$$





































$$pIC_{50} = 11.1047 - 0.0606RDF105m - 19.8127G2e + 0.2046H - 048 + 0.1602F07[C - S] \quad (\text{Model 1a})$$

$$N_{tr} = 29, N_{ex} = 7, Q_{loo}^2 = 0.7465, R_{tr}^2 = 0.8674, R_{adj}^2 = 0.8452, K_{xx} = 0.2749, \Delta K = 0.1439, RMSE_{tr} = 0.1507, RMSE_{cv} = 0.2083, RMSE_{ex} = 0.2058, Sy = 0.1656, F = 39.2325, Q^2-F^1 = 0.8223, Q^2-F^2 = 0.7872, Q^2-F^3 = 0.7525, CCC_{tr} = 0.9290, CCC_{cv} = 0.8639, CCC_{ex} = 0.9036, r^2m_{av} = 0.7928, r^2m_{de} = 0.1061, MAE_{tr} = 0.1196, MAE_{cv} = 0.1558, MAE_{ex} = 0.1515, RSS_{tr} = 0.6585, PRESS_{cv} = 1.2582, PRESS_{ex} = 0.2966, R_{LMO}^2 = 0.8785, Q_{LMO}^2 = 0.7569 \quad (\text{Table 2}).$$

$$pIC_{50} = 21.5026 - 3.6217BEHm7 - 0.0319RDF045m - 0.0461RDF025e + 0.1815F07[N - O] \quad (\text{Model 2})$$

$$N_{tr} = 36, Q_{loo}^2 = 0.7810, R_{tr}^2 = 0.8502, R_{adj}^2 = 0.8309, K_{xx} = 0.3053, \Delta K = 0.1369, RMSE_{tr} = 0.1654, RMSE_{cv} = 0.2000, Sy = 0.1783, F = 44.0019, CCC_{cv} = 0.8820, MAE_{tr} = 0.1307, MAE_{cv} = 0.1555, RSS_{tr} = 0.9854, PRESS_{cv} = 1.4407, R_{LMO}^2 = 0.8576, Q_{LMO}^2 = 0.7831.$$

**Table 1** IASs used in present work along with their  $pIC_{50}$  values

| S. no. | R <sup>1</sup>    | R <sup>2</sup>  | IC <sub>50</sub> (nM) | $pIC_{50}$ (M) |
|--------|-------------------|---|-----------------------|----------------|
| 1      | 5-Cl              |    | 3.3                   | 8.481          |
| 2      | 5-Br              |    | 1.3                   | 8.886          |
| 3      | 5-NO <sub>2</sub> |    | 2.5                   | 8.602          |
| 4      | 5-Cl, 4-F         |    | 3.9                   | 8.409          |
| 5      | 5-Cl              |    | 1.3                   | 8.886          |
| 6      | 5-Br              |    | 3.7                   | 8.432          |
| 7      | 5-NO <sub>2</sub> |    | 3.1                   | 8.509          |
| 8      | 5-Cl, 4-F         |    | 3.9                   | 8.409          |
| 9      | 5-Cl              |    | 1.9                   | 8.721          |
| 10     | 5-Br              |    | 3.4                   | 8.469          |
| 11     | 5-NO <sub>2</sub> |    | 5.8                   | 8.237          |
| 12     | 5-Cl, 4-F         |    | 2.5                   | 8.602          |
| 13     | 5-Cl              |    | 5.7                   | 8.244          |
| 14     | 5-Br              |    | 5.7                   | 8.244          |
| 15     | 5-NO <sub>2</sub> |    | 6.2                   | 8.208          |
| 16     | 5-Cl, 4-F         |    | 5.8                   | 8.237          |
| 17     | 5-Cl              |    | 17                    | 7.77           |
| 18     | 5-Br              |    | 16                    | 7.796          |
| 19     | 5-NO <sub>2</sub> |    | 16                    | 7.796          |
| 20     | 5-Cl, 4-F         |    | 28                    | 7.553          |
| 21     | 5-Cl              |    | 8.8                   | 8.056          |
| 22     | 5-Br              |    | 170                   | 6.77           |
| 23     | 5-NO <sub>2</sub> |    | 8                     | 8.097          |
| 24     | 5-Cl, 4-F         |  | 13                    | 7.886          |
| 25     | 5-Cl              |  | 5.7                   | 8.244          |
| 26     | 5-Br              |  | 14                    | 7.854          |
| 27     | 5-NO <sub>2</sub> |  | 6.8                   | 8.167          |
| 28     | 5-Cl, 4-F         |  | 14                    | 7.854          |
| 29     | 5-Cl              |  | 6.5                   | 8.187          |
| 30     | 5-Br              |  | 6.4                   | 8.194          |
| 31     | 5-NO <sub>2</sub> |  | 6.9                   | 8.161          |
| 32     | 5-Cl, 4-F         |  | 5.5                   | 8.26           |
| 33     | 5-Cl              |  | 26                    | 7.585          |
| 34     | 5-Br              |  | 29                    | 7.538          |
| 35     | 5-NO <sub>2</sub> |  | 29                    | 7.538          |
| 36     | 5-Cl, 4-F         |  | 19                    | 7.721          |

$$pIC_{50} = 21.5026 - 3.6217BEHm7 - 0.0319RDF045m - 0.0461RDF025e + 0.1815F07[N - O] \quad (\text{Model 2a})$$

$N_{tr} = 29$ ,  $N_{ex} = 7$ ,  $Q^2_{loo} = 0.7531$ ,  $R^2_{tr} = 0.8535$ ,  $R^2_{adj} = 0.8291$ ,  $K_{xx} = 0.2540$ ,  $\Delta K = 0.1597$ ,  $RMSE_{tr} = 0.1680$ ,  $RMSE_{cv} = 0.2181$ ,  $RMSE_{ex} = 0.1675$ ,  $Sy = 0.1847$ ,  $F = 34.9549$ ,  $Q^2 - F^1 = 0.8097$ ,  $Q^2 - F^2 = 0.7633$ ,  $Q^2 - F^3 = 0.8543$ ,  $CCC_{tr} = 0.9210$ ,  $CCC_{cv} = 0.8676$ ,  $CCC_{ex} = 0.8874$ ,  $r^2_{mav} = 0.7674$ ,  $r^2_{mde} = 0.0137$ ,

$MAE_{tr} = 0.1273$ ,  $MAE_{cv} = 0.1599$ ,  $MAE_{ex} = 0.1482$ ,  $RSS_{tr} = 0.8185$ ,  $PRESS_{cv} = 1.3796$ ,  $PRESS_{ex} = 0.1965$ ,  $R^2_{LMO} = 0.8641$ ,  $Q^2_{LMO} = 0.7664$  (Table 3).

The symbols have their usual meaning (Chirico and Gramatica, 2011, 2012; Gramatica 2013; Gramatica *et al.*, 2007; Kim *et al.*, 2007; Kovarich *et al.*, 2012; Liu *et al.*, 2008; Mahajan *et al.*, 2013; Masand *et al.*, 2010, 2012, 2013). The high values of  $R$ ,  $R^2$ ,  $R^2_{adj}$ ,  $R^2_{cv}$ , and  $F$  with low value of  $Sy$ ,  $RMSE_{train}$ , and  $PRESS$  confirm statistical robustness of the equation. The close values of  $R^2$ ,  $R^2_{cv}$ ,  $R^2_{LMO}$ , and  $R^2_{LSO}$  reveal that the equation is statistically



**Table 2** Experimental and predicted  $pIC_{50}$  by Model 1

| ID | Status   | Exp. $pIC_{50}$ | Pred. fitting $pIC_{50}$ | Pred.fit. res. | Pred. LOO | Pred. LOO res. | HAT i/i |
|----|----------|-----------------|--------------------------|----------------|-----------|----------------|---------|
| 1  | Training | 8.4810          | 8.8284                   | 0.3474         | 8.8830    | 0.4020         | 0.1358  |
| 2  | Training | 8.8860          | 8.6661                   | −0.2199        | 8.6452    | −0.2408        | 0.0870  |
| 3  | Training | 8.6020          | 8.6317                   | 0.0297         | 8.6352    | 0.0332         | 0.1064  |
| 4  | Training | 8.4090          | 8.3580                   | −0.0510        | 8.3508    | −0.0582        | 0.1241  |
| 5  | Training | 8.8860          | 8.7696                   | −0.1164        | 8.7527    | −0.1333        | 0.1264  |
| 6  | Training | 8.4320          | 8.4582                   | 0.0262         | 8.4635    | 0.0315         | 0.1661  |
| 7  | Training | 8.5090          | 8.5530                   | 0.0440         | 8.5567    | 0.0477         | 0.0774  |
| 8  | Training | 8.4090          | 8.6580                   | 0.2490         | 8.6795    | 0.2705         | 0.0793  |
| 9  | Training | 8.7210          | 8.6574                   | −0.0636        | 8.6517    | −0.0693        | 0.0815  |
| 10 | Training | 8.4690          | 8.4930                   | 0.0240         | 8.4961    | 0.0271         | 0.1141  |
| 11 | Training | 8.2370          | 8.3996                   | 0.1626         | 8.4204    | 0.1834         | 0.1137  |
| 12 | Training | 8.6020          | 8.5546                   | −0.0474        | 8.5509    | −0.0511        | 0.0735  |
| 13 | Training | 8.2440          | 8.1285                   | −0.1155        | 8.1091    | −0.1349        | 0.1435  |
| 14 | Training | 8.2440          | 8.2161                   | −0.0279        | 8.2120    | −0.0320        | 0.1304  |
| 15 | Training | 8.2080          | 8.0715                   | −0.1365        | 8.0417    | −0.1663        | 0.1792  |
| 16 | Training | 8.2370          | 8.2925                   | 0.0555         | 8.3019    | 0.0649         | 0.1449  |
| 17 | Training | 7.7700          | 7.7414                   | −0.0286        | 7.7382    | −0.0318        | 0.0998  |
| 18 | Training | 7.7960          | 7.8741                   | 0.0781         | 7.8832    | 0.0872         | 0.1045  |
| 19 | Training | 7.7960          | 7.8371                   | 0.0411         | 7.8420    | 0.0460         | 0.1068  |
| 20 | Training | 7.5530          | 7.6640                   | 0.1110         | 7.6826    | 0.1296         | 0.1440  |
| 21 | Training | 8.0560          | 7.9515                   | −0.1045        | 7.9364    | −0.1196        | 0.1265  |
| 22 | Training | 6.7700          | 7.1549                   | 0.3849         | 7.4077    | 0.6377         | 0.3964  |
| 23 | Training | 8.0970          | 7.7646                   | −0.3324        | 7.7409    | −0.3561        | 0.0667  |
| 24 | Training | 7.8860          | 7.9092                   | 0.0232         | 7.9121    | 0.0261         | 0.1083  |
| 25 | Training | 8.2440          | 8.1489                   | −0.0951        | 8.1383    | −0.1057        | 0.1010  |
| 26 | Training | 7.8540          | 7.9413                   | 0.0873         | 7.9488    | 0.0948         | 0.0789  |
| 27 | Training | 8.1670          | 8.0299                   | −0.1371        | 8.0201    | −0.1469        | 0.0667  |
| 28 | Training | 7.8540          | 7.6784                   | −0.1756        | 7.5425    | −0.3115        | 0.4365  |
| 29 | Training | 8.1870          | 7.9708                   | −0.2162        | 7.9255    | −0.2615        | 0.1733  |
| 30 | Training | 8.1940          | 7.9855                   | −0.2085        | 7.9430    | −0.2510        | 0.1695  |
| 31 | Training | 8.1610          | 8.1820                   | 0.0210         | 8.1860    | 0.0250         | 0.1602  |
| 32 | Training | 8.2600          | 8.2790                   | 0.0190         | 8.2838    | 0.0238         | 0.2004  |
| 33 | Training | 7.5850          | 7.8934                   | 0.3084         | 7.9385    | 0.3535         | 0.1275  |
| 34 | Training | 7.5380          | 7.4051                   | −0.1329        | 7.3454    | −0.1926        | 0.3098  |
| 35 | Training | 7.5380          | 7.7250                   | 0.1870         | 7.7393    | 0.2013         | 0.0710  |
| 36 | Training | 7.7210          | 7.7304                   | 0.0094         | 7.7311    | 0.0101         | 0.0691  |

stable apropos to inclusion–exclusion of molecules in dataset. In addition, the value of CCCex is higher than the threshold value ( $>0.85$ ) that indicates high external predictivity of the models (Chirico and Gramatica, 2011, 2012; Gramatica 2013; Gramatica *et al.*, 2007; Kim *et al.*, 2007; Liu and Gramatica, 2007; Liu *et al.*, 2008). The plot between experimental and predicted  $pIC_{50}$  (depicted in Fig. 2) reveals a good relation and predictive ability of the equation.

## Results and discussions

### Validation and interpretation of QSAR models

Appropriate validation and interpretation of QSAR models are very crucial to prove that the models are very useful for steering the future lead optimization. For the QSAR models developed in present study, apparently the anti-HIV activity varies with 2D and 3D descriptors viz. *RDF105m* (Radial

**Table 3** Experimental and predicted  $pIC_{50}$  by model 2


| ID | Status   | Exp. $pIC_{50}$ | Pred. fitting $pIC_{50}$ | Pred. fit. res. | Pred. LOO | Pred. LOO res. | HAT i/i |
|----|----------|-----------------|--------------------------|-----------------|-----------|----------------|---------|
| 1  | Training | 8.4810          | 8.5594                   | 0.0784          | 8.5655    | 0.0845         | 0.0732  |
| 2  | Training | 8.8860          | 8.5972                   | −0.2888         | 8.5748    | −0.3112        | 0.0721  |
| 3  | Training | 8.6020          | 8.8402                   | 0.2382          | 8.8967    | 0.2947         | 0.1917  |
| 4  | Training | 8.4090          | 8.4614                   | 0.0524          | 8.4659    | 0.0569         | 0.0791  |
| 5  | Training | 8.8860          | 8.6337                   | −0.2523         | 8.6123    | −0.2737        | 0.0780  |
| 6  | Training | 8.4320          | 8.3630                   | −0.0690         | 8.3567    | −0.0753        | 0.0838  |
| 7  | Training | 8.5090          | 8.3950                   | −0.1140         | 8.3680    | −0.1410        | 0.1916  |
| 8  | Training | 8.4090          | 8.4314                   | 0.0224          | 8.4340    | 0.0250         | 0.1034  |
| 9  | Training | 8.7210          | 8.4457                   | −0.2753         | 8.4208    | −0.3002        | 0.0830  |
| 10 | Training | 8.4690          | 8.4908                   | 0.0218          | 8.4925    | 0.0235         | 0.0755  |
| 11 | Training | 8.2370          | 8.4536                   | 0.2166          | 8.4977    | 0.2607         | 0.1691  |
| 12 | Training | 8.6020          | 8.5341                   | −0.0679         | 8.5285    | −0.0735        | 0.0763  |
| 13 | Training | 8.2440          | 8.2826                   | 0.0386          | 8.2876    | 0.0436         | 0.1136  |
| 14 | Training | 8.2440          | 8.2675                   | 0.0235          | 8.2703    | 0.0263         | 0.1068  |
| 15 | Training | 8.2080          | 8.1797                   | −0.0283         | 8.1779    | −0.0301        | 0.0598  |
| 16 | Training | 8.2370          | 8.1567                   | −0.0803         | 8.1478    | −0.0892        | 0.1004  |
| 17 | Training | 7.7700          | 7.9690                   | 0.1990          | 7.9912    | 0.2212         | 0.1002  |
| 18 | Training | 7.7960          | 7.7137                   | −0.0823         | 7.7005    | −0.0955        | 0.1386  |
| 19 | Training | 7.7960          | 7.9751                   | 0.1791          | 7.9838    | 0.1878         | 0.0458  |
| 20 | Training | 7.5530          | 7.6461                   | 0.0931          | 7.6736    | 0.1206         | 0.2277  |
| 21 | Training | 8.0560          | 7.8979                   | −0.1581         | 7.8685    | −0.1875        | 0.1564  |
| 22 | Training | 6.7700          | 7.1359                   | 0.3659          | 7.2993    | 0.5293         | 0.3087  |
| 23 | Training | 8.0970          | 7.9138                   | −0.1832         | 7.8712    | −0.2258        | 0.1886  |
| 24 | Training | 7.8860          | 7.7441                   | −0.1419         | 7.7121    | −0.1739        | 0.1839  |
| 25 | Training | 8.2440          | 8.1320                   | −0.1120         | 8.1173    | −0.1267        | 0.1159  |
| 26 | Training | 7.8540          | 7.8517                   | −0.0023         | 7.8512    | −0.0028        | 0.1706  |
| 27 | Training | 8.1670          | 8.2215                   | 0.0545          | 8.2287    | 0.0617         | 0.1162  |
| 28 | Training | 7.8540          | 7.7434                   | −0.1106         | 7.7207    | −0.1333        | 0.1705  |
| 29 | Training | 8.1870          | 8.3979                   | 0.2109          | 8.4341    | 0.2471         | 0.1466  |
| 30 | Training | 8.1940          | 8.1203                   | −0.0737         | 8.1040    | −0.0900        | 0.1806  |
| 31 | Training | 8.1610          | 8.5957                   | 0.4347          | 8.6679    | 0.5069         | 0.1425  |
| 32 | Training | 8.2600          | 8.1963                   | −0.0637         | 8.1803    | −0.0797        | 0.2017  |
| 33 | Training | 7.5850          | 7.6314                   | 0.0464          | 7.6387    | 0.0537         | 0.1356  |
| 34 | Training | 7.5380          | 7.3513                   | −0.1867         | 7.2575    | −0.2805        | 0.3345  |
| 35 | Training | 7.5380          | 7.6156                   | 0.0776          | 7.6345    | 0.0965         | 0.1957  |
| 36 | Training | 7.7210          | 7.6584                   | −0.0626         | 7.6528    | −0.0682        | 0.0820  |

Distribution Function—10.5/weighted by atomic masses), *G2e* (2nd component symmetry directional WHIM index/weighted by atomic Sanderson electronegativities), *H-048* (H attached to C2(sp<sup>3</sup>)/C1(sp<sup>2</sup>)/C0(sp)), *F07[C–S]* (frequency of occurrence of C–S at a topological distance of seven), *BEHm7* (highest eigen value *n*. 7 of Burden matrix/weighted by atomic masses), *RDF045m* (Radial Distribution Function—4.5/weighted by atomic masses), *RDF025e* (Radial Distribution Function—2.5/weighted by atomic Sanderson electronegativities), and *F07[N–O]* (frequency of occurrence of N–O at a topological distance of seven).

#### Interpretation of model 1 and 1a

The positive coefficients for *H-048* and *F07[C–S]* reveal that they contribute positively toward anti-HIV activity whereas reverse is true for *RDF105m* and *G2e*. This fact is supported by the comparison of **1** (EC<sub>50</sub> = 3.3 nM) with **5** (EC<sub>50</sub> = 1.3 nM), **14** (EC<sub>50</sub> = 5.7 nM) with **26** (EC<sub>50</sub> = 14 nM), **2** (EC<sub>50</sub> = 1.3 nM) with **18** (EC<sub>50</sub> = 16 nM), and **10** (EC<sub>50</sub> = 3.4 nM) with **22** (EC<sub>50</sub> = 170 nM) as well as **13–16** (EC<sub>50</sub> = 5.7–6.2 nM) with **33–36** (EC<sub>50</sub> = 19–26 nM).





**Fig. 2** Plot between experimental and predicted  $pIC_{50}$  by model 1 (blue) and 2 (red) (Color figure online)

### Interpretation of model 2 and 2a


The positive coefficient of  $F07[N-O]$  shows that increase in the frequency of occurrence of N–O at topological distance of seven is beneficial for escalating the activity. This is confirmed by the high activity of compounds **1–16**, having high occurrence of N–O at topological distance of seven, than **17–36**. The negative coefficients of  $BEHm7$ ,  $RDF045m$ , and  $RDF025e$  indicate that their values should


be as low as possible. These observations are vindicated by the difference in the activity of **1** ( $EC_{50} = 3.3$  nM) with **5** ( $EC_{50} = 1.3$  nM), and **2** ( $EC_{50} = 1.3$  nM) with **40** ( $EC_{50} = 16$  nM).

The IASs possess varieties of conformations (Fig. 3). The correlation of biological activity with different descriptors viz. RDF and BEH indicates that IASs adapt a new conformation to have appropriate interactions with the receptor, as supported by the docking analysis.

The radial distribution function (RDF) descriptors are based on the distance distribution of the compounds. The RDF descriptors of a molecule of  $n$  atoms can be interpreted as the probability distribution of finding an atom in a spherical volume of radius  $R$ . In energy-optimized conformation, neither the heavy nor highly electronegative atoms are close. But, the correlation of activity with 3D-descriptor  $RDF045m$  reveals that during their interaction with the receptor, IASs adapt a specific conformation, as vindicated by the molecular docking analysis (Fig. 4), such that the heavy atoms are closer (within 4.5 Å) which results in internal repulsion, however, with augmentation in activity. Similarly, the descriptor  $RDF025e$  underlines the significance of the electrostatic environment. Figure 4 represents the conformations of molecules in docking pose and energy-optimized condition. As it can be observed, the

**Fig. 3** Different tautomeric and conformational forms of Indole-2-carboxamides





**Fig. 4** Graphical representation of RDF descriptors for different conformations of **2**, **18**, **10**, and **22**, respectively, the compounds with the highest and lowest anti-HIV-1 activities

main difference is the presence of electronegative atoms like O and N in the inner regions of the compounds, specifically inside 2.5 Å.

## Molecular docking

### Keto form


The prominent interactions between keto form of the most active molecule **2** and receptor are arene-cation, hydrophobic and H-bonding in nature (Fig. 5). It interacts with **Lys102** and **Lys347** (2.25 Å, 14 %) due to H-bonding, with **Asp320** and **Glu344** through hydrophobic interaction, and with **Lys323** (2.35 Å, 11 %) due to arene-cation interaction (see Fig. 5). In the docking pose, the NH (ring 2) and keto group of amide are oriented on the same side forming a NH ( $\delta^-$ ) and C=O ( $\delta^-$ ) pharmacophore site. The rings 1 and 3 act as lipophilic and are responsible for interaction with hydrophobic region of the pocket. In

addition, the water (close to **Lys102**) inside the active site acts as bridge between drug and receptor due to the H-bond formation (2.57 Å, 23 %).


### Enol form

The enol form of compound **2** interacts differently with receptor than the keto form (Fig. 5). For the enol form, the major interactions are H-bond formation and hydrophobic in nature. It interacts with **Lys103** (2.3 Å, 22 %) due to H-bonding, and with **Pro176**, **Asp177**, **Ile178**, and **Val179** due to mild polar and hydrophobic interactions. Interestingly, the -OH group formed due to keto-enol tautomerization is oriented away from NH of ring 2. Surprisingly, the water molecule which plays a crucial role for the keto form does not play any role in docking of enol form.

Figure 6 depicts the summary of SAR, QSAR, and molecular docking analyses of IASs.



**Fig. 5** Docking poses for keto and enol forms of the most active compound **1**



**Fig. 6** Summary of SAR, QSAR, and docking analyses

From docking analysis, keto and enol form of IASs have not only different orientations inside the active site but also different amino acid residues, level, and atoms are involved in deciding the interactions. Literature survey reveals that the drugs which are capable of releasing the buried water molecule from active site of receptor possess exceptionally high binding entropy as well as gain in selectivity is also possible. Thus, the stabilization of  $-OH$  group formed due to keto–enol tautomerization by either chemical transformation or by some other method is an attractive area for significant rise in the activity and selectivity of IASs as anti-HIV activity.

## Conclusions

In conclusion, the QSAR and docking analyses presented here accentuate the important structural features governing the anti-HIV activity of IASs. Moreover, they proffer supportive insinuations for the design of new IASs with improved activity profile. The models are useful to design new anti-HIV IASs with better activity, before their synthesis.

**Acknowledgments** We are thankful to Dr. K. N. Patil, Amravati and Dr. Ashraf Ali, Singapore for useful discussions. Sincere thanks to Dr. F. C. Raghuvanshi for encouragement and facilities.

## References

- Chirico N, Gramatica P (2011) Real external predictivity of QSAR models: how to evaluate it? comparison of different validation criteria and proposal of using the concordance correlation coefficient. *J Chem Inf Model* 51(9):2320–2335
- Chirico N, Gramatica P (2012) Real external predictivity of QSAR models. Part 2. New intercomparable thresholds for different validation criteria and the need for scatter plot inspection. *J Chem Inf Model* 52(8):2044–2058
- Doweyko AM (2008) QSAR: dead or alive? *J Comput Aided Mol Des* 22(2):81–89
- Golbraikh A, Tropsha A (2002) Beware of  $q^2$ ! *J Mol Graph Model* 20(4):269–276
- Gramatica P (2013) On the development and validation of QSAR models. *Methods Mol Biol* 930:499–526
- Gramatica P, Papa E (2007) Screening and ranking of POPs for global half-life: QSAR approaches for prioritization based on molecular structure. *Environ Sci Technol* 41(8):2833–2839
- Gramatica P, Pilutti P, Papa E (2007) Approaches for externally validated QSAR modelling of nitrated polycyclic aromatic hydrocarbon mutagenicity. *SAR QSAR Environ Res* 18(1–2): 169–178
- Kim JH, Gramatica P, Kim MG, Kim D, Tratnyek PG (2007) QSAR modelling of water quality indices of alkylphenol pollutants. *SAR QSAR Environ Res* 18(7–8):729–743
- Kovarich S, Papa E, Li J, Gramatica P (2012) QSAR classification models for the screening of the endocrine-disrupting activity of perfluorinated compounds. *SAR QSAR Environ Res* 23(3–4): 207–220
- La Regina G, Coluccia A, Brancale A, Piscitelli F, Gatti V, Maga G, Samuele A, Pannecouque C, Schols D, Balzarini J, Novellino E, Silvestri R (2011) Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide. *J Med Chem* 54(6):1587–1598
- Liu H, Gramatica P (2007) QSAR study of selective ligands for the thyroid hormone receptor beta. *Bioorg Med Chem* 15(15): 5251–5261
- Liu H, Papa E, Gramatica P (2008) Evaluation and QSAR modeling on multiple endpoints of estrogen activity based on different bioassays. *Chemosphere* 70(10):1889–1897
- Mahajan DT, Masand VH, Patil KN, Ben Hadda T, Jawarkar RD, Thakur SD, Rastija V (2012) CoMSIA and POM analyses of anti-malarial activity of synthetic prodiginines. *Bioorg Med Chem Lett* 22(14):4827–4835
- Mahajan DT, Masand VH, Patil KN, Hadda TB, Rastija V (2013) Integrating GUSAR and QSAR analyses for antimalarial activity of synthetic prodiginines against multi drug resistant strain. *Med Chem Res* 22:2284–2292

- Martin TM, Harten P, Young DM, Muratov EN, Golbraikh A, Zhu H, Tropsha A (2012) Does rational selection of training and test sets improve the outcome of QSAR modeling? *J Chem Inf Model* 52(10):2570–2578
- Masand VH, Jawarkar RD, Patil KN, Nazerruddin GM, Bajaj SO (2010) Correlation potential of Wiener index and molecular refractivity vis-a'-vis antimalarial activity of xanthone derivatives. *Org Chem* 6(1):30–38
- Masand VH, Jawarkar RD, Mahajan DT, Hadda TB, Sheikh J, Patil KN (2012) QSAR and CoMFA studies of biphenyl analogs of the anti-tuberculosis drug (6S)-2-nitro-6-([4-(trifluoromethoxy)benzyl]oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine(PA-824). *Med Chem Res* 21:2624–2629
- Masand VH, Mahajan DT, Patil KN, Hadda TB, Youssoufi MH, Jawarkar RD, Shibi IG (2013) Optimization of antimalarial activity of synthetic prodiginines: QSAR, GUSAR, and CoMFA analyses. *Chem Biol Drug Des* 81(4):527–536
- Sushko I, Novotarskyi S, Korner R, Pandey AK, Cherkasov A, Li J, Gramatica P, Hansen K, Schroeter T, Muller KR, Xi L, Liu H, Yao X, Oberg T, Hormozdiari F, Dao P, Sahinalp C, Todeschini R, Polishchuk P, Artemenko A, Kuz'min V, Martin TM, Young DM, Fourches D, Muratov E, Tropsha A, Baskin I, Horvath D, Marcou G, Muller C, Varnek A, Prokopenko VV, Tetko IV (2010) Applicability domains for classification problems: benchmarking of distance to models for Ames mutagenicity set. *J Chem Inf Model* 50(12):2094–2111
- Tropsha A (2010) Best practices for QSAR model development, validation, and exploitation. *Mol Inf* 29:476–488
- WHO Report (2011) <http://www.who.int/>. Accessed 23 Nov 2012